Katz / Benacerraf The Role of Products of the Histocompatibility Gene Complex in Immune Responses

1. Auflage 2014
ISBN: 978-1-4832-7344-0
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 802 Seiten

The Role of Products of the Histocompatibility Gene Complex in Immune Responses documents the proceedings of a conference held on 3-7 November 1975, which brought together an international group of scientists spanning three independent disciplines-genetics and immunogenetics, molecular biochemistry, and immunobiology-with clinical medicine overlapping these disciplines. This volume contains 42 papers organized according to the eight sessions held at the conference. The papers in Session I examined the genetics of the major histocompatibility complex. Session II presented studies on the biology of mixed lymphocyte interactions and cell-mediated cytotoxicity reactions. Session III discussed immune response gene systems while Session IV dealt with the genetic control of cell interactions. The papers in Session V covered idiotypic determinants on T cell receptors. Session VI investigated the properties of histocompatibility gene products involved in regulation of immune responses. Session VII focused on the biochemistry and immunocytology of cell surface products of the major histocompatibility complex. Finally, Session VIII discussed interrelationships between products of the major histocompatibility complex and their relevance to disease.

Autoren/Hrsg.

Katz, David H.

Benacerraf, Baruj

Inhaltsverzeichnis

1;Front Cover;1
2;The Role of Products of the Histocompatibility Gene Complex in
Immune Responses;4
3;Copyright Page;5
4;Table of Contents;6
5;Participants;12
6;Preface;16
7;PHOTOGRAPHS OF PARTICIPANTS;20
8;SESSION I: Genetics of the Major Histocompatibility Complex;24
8.1;CHAPTER 1. GENETIC RESOLUTION OF THE PRODUCTS AND FUNCTIONS OF I AND S REGION GENES OF THE MOUSE H-2
COMPLEX;26
8.1.1;Abstract;26
8.1.2;INTRODUCTION;27
8.1.3;GENETIC ORGANIZATION OF THE H-2
COMPLEX;27
8.1.4;THE ROLE OF THE S
REGION IN COMPLEMENT FUNCTIONS;28
8.1.5;THE SEROLOGICALLY DETECTED 1 REGION PRODUCTS:
GENETIC CONTROL, PROPERTIES, FUNCTIONS;33
8.1.6;POSSIBLE PATTERNS OF GENETIC ORGANIZATION OF THE 1 REGION;41
8.1.7;ACKNOWLEDGMENTS;45
8.1.8;REFERENCES;46
8.1.9;DISCUSSION FOLLOWING DONALD SHREFFLER;51
8.2;CHAPTER 2. THE GENETICS OF THE MAJOR HISTOCOMPATIBILITY COMPLEX IN
MAN, HLA;54
8.2.1;INTRODUCTION;55
8.2.2;THE HLA SUPERGENE AND THE 6TH CHROMOSOME;55
8.2.3;THE GENETICS OF THE D(MLC-s) LOCUS;58
8.2.4;HLA AND DISEASE ASSOCIATIONS;66
8.2.5;HLA AND IMMUNE RESPONSE;67
8.2.6;REFERENCES;69
8.2.7;DISCUSSION FOLLOWING JON van ROOD;73
8.3;CHAPTER 3. MOLECULAR RELATIONSHIPS OF la ANTIGENS CONTROLLED BY THE SAME
AND BY DIFFERENT SUBREGIONS OF THE I REGION;76
8.3.1;ACKNOWLEDGEMENTS;80
8.3.2;REFERENCES;81
8.4;CHAPTER 4. Br AND Wh, B CELL ANTIGENS IN GLUTEN SENSITIVE ENTEROPATHY
AND DERMATITIS HERPETIFORMIS;82
8.4.1;INTRODUCTION;82
8.4.2;MATERIALS AND METHODS;84
8.4.3;DISCUSSION;88
8.4.4;ACKNOWLEDGMENT;90
8.4.5;REFERENCES;91
8.5;CHAPTER 5. RECENT STUDIES OF la LIKE ANTIGENS AND COMPLEMENT COMPONENTS
RELATING TO THE HUMAN HISTOCOMPATIBILITY SYSTEM;94
8.5.1;THE ROCKEFELLER UNIVERSITY AND
SLOAN KETTERING INSTITUTE;94
8.5.2;COMPLEMENT-MHC RELATIONSHIPS;96
8.5.3;REFERENCES;98
8.6;CHAPTER 6.
NATURAL KILLER CELLS IN THE MOUSE;100
8.6.1;INTRODUCTION;100
8.6.2;SPECIFICITY OF
NATURAL KILLER CELLS;101
8.6.3;AGE VARIATION OF NATURAL KILLER
CELL ACTIVITY;102
8.6.4;EFFECTOR CELL ANALYSIS OF NATURAL KILLER
CELLS;102
8.6.5;GENETIC ANALYSIS OF NATURAL KILLER CELL ACTIVITY;104
8.6.6;IN VIVO RELEVANCE OF
NATURAL KILLER CELLS;104
8.6.7;CONCLUSIONS;106
8.6.8;ACKNOWLEDGEMENTS;107
8.6.9;REFERENCES;107
8.7;CHAPTER 7. EVIDENCE FOR THE ASSOCIATION OF SPECIFICITY la.3
WITH AN I-A REGION MOLECULE;110
8.7.1;REFERENCES;111
8.8;GENERAL DISCUSSION - SESSION I:
GENETICS OF THE MAJOR HISTOCOMPATIBILITY COMPLEX;114
9;SESSION II: The Biology of Mixed Lymphocyte Interactions and Cell-mediated Cytotoxicity Reactions;124
9.1;CHAPTER 8. GENETIC AND CELLULAR ASPECTS OF MIXED LEUKOCYTE CULTURE AND
CELL MEDIATED LYMPHOLYSIS REACTIONS;126
9.1.1;GENETIC CONTROL OF MLC — THE MHC LD SYSTEM;128
9.1.2;GENETIC CONTROL OF CML — "LD-SD COLLABORATION;129
9.1.3;CELLULAR RECOGNITION OF MHC ANTIGENS;131
9.1.4;SECONDARY RESPONSES IN VITRO;133
9.1.5;PRIMED LD TYPING (PLT) TEST;133
9.1.6;RESTIMULATION OF CYTOXICITY;136
9.1.7;MODEL — AN ATTEMPT AT SYNTHESIS;139
9.1.8;IN VIVO LD-SD COLLABORATION;144
9.1.9;SUMMARY;146
9.1.10;REFERENCES;147
9.1.11;ACKNOWLEDGEMENT;151
9.1.12;DISCUSSION FOLLOWING FRITZ BACH;152
9.2;CHAPTER 9. BIFUNCTIONAL HISTOCOMPATIBILITY-LINKED REGULATION OF CELL MEDIATED LYMPHOLYSIS TO MODIFIED AUTOLOGOUS CELL
SURFACE COMPONENTS;156
9.2.1;INTRODUCTION;157
9.2.2;REQUIREMENT FOR H-2 HOMOLOGY OF MODIFIED TARGET CELLS WITH
MODIFIED STIMULATING CELLS AND/OR RESPONDING LYMPHOCYTES;158
9.2.3;SPECIFICITY OF CYTOTOXICITY AS A FUNCTION OF THE MODIFYING AGENT;164
9.2.4;EFFECTOR CELL SPECIFICITY: MODIFIED AUTOLOGOUS H-2
PRODUCTS VS HAPTEN;164
9.2.5;CONCLUSIONS AND SPECULATIONS;173
9.2.6;ACKNOWLEDGMENTS;175
9.2.7;REFERENCES;175
9.2.8;DISCUSSION FOLLOWING GENE SHEARER;178
9.3;CHAPTER 10.
THE ROLE OF la ANTIGENS IN MLC STIMULATION;182
9.3.1;INTRODUCTION;182
9.3.2;MATERIALS AND METHODS;183
9.3.3;RESULTS;183
9.3.4;DISCUSSION;186
9.3.5;REFERENCES;187
9.4;CHAPTER 11. H-2 ASSOCIATED MLR DETERMINANTS: IMMUNOGENETICS OF THE LOC
1 AND THEIR PRODUCTS;190
9.4.1;MAPPING OF MLR GENES;190
9.4.2;MLR ASSAY IN RECOMBINANT SCREENING;191
9.4.3;THE INHIBITION OF MLR WITH ANTI-la SERA;193
9.4.4;ACKNOWLEDGMENTS;200
9.4.5;REFERENCES;200
9.5;CHAPTER 12. RESPONSES OF ALLOANTIGEN REACTIVE LYMPHOCYTES TO CONVENTIONAL
ANTIGENS;202
9.5.1;REFERENCES;205
9.6;CHAPTER 13. EVIDENCE FOR SEVERAL CLOSELY LINKED GENES INVOLVED
IN GENERATION OF PROLIFERATION IN MLC.;206
9.6.1;INTRODUCTION;207
9.6.2;EVIDENCE THAT TWO D-LOCUS HOMOZYGOUS TYPING
CELLS BELONG TO THE SAME DW SPECIFICITY GROUP.;207
9.6.3;EVIDENCE FOR DIFFERENCES IN D-LOCUS SPECIFICITY
BETWEEN TWO TYPING CELLS OF THE DW4 SPECIFICITY GROUP;208
9.6.4;CONCLUSIONS;214
9.6.5;ACKNOWLEDGEMENTS;215
9.6.6;REFERENCES;215
9.7;CHAPTER 14.
SUPPRESSIVE INTERACTIONS BETWEEN DIFFERENT MLR LOCI;216
9.7.1;INTRODUCTION;216
9.7.2;EXPERIMENTAL DETAILS;217
9.7.3;RESULTS;218
9.7.4;DISCUSSION;221
9.7.5;ACKNOWLEDGMENTS;224
9.7.6;REFERENCES;224
9.8;CHAPTER 15. DOES THE APPARENT H-2 COMPATIBILITY REQUIREMENT FOR VIRUS–SPECIFIC T CELL-MEDIATED CYTOLYSIS REFLECT T CELL SPECIFICITY FOR "ALTERED SELF" OR PHYSIOLOGICAL
INTERACTION MECHANISMS;226
9.8.1;ACKNOWLEDGMENTS;232
9.8.2;REFERENCES;233
9.9;GENERAL DISCUSSION - SESSION II:
THE BIOLOGY OF MIXED LYMPHOCYTE INTERACTIONS AND CELL-MEDIATED CYTOTOXICITY REACTIONS;236
10;SESSION III:
Immune Response (Ir) Gene Systems;246
10.1;CHAPTER 16. THE NATURE AND FUNCTION OF SPECIFIC H-LINKED
IMMUNE RESPONSE GENES AND IMMUNE SUPPRESSION GENES BARUJ BENACERRAF AND MARTIN DORF;248
10.1.1;THE ACTIVITIES OF COMPLEMENTING HISTOCOMPATIBILITY-LINKED
Ir GENES IN THE CONTROL OF IMMUNE RESPONSES TO SYNTHETIC ANTIGENS;248
10.1.2;CIS-TRANS EFFECTS IN THE COMPLEMENTING OF a AND ß
GENES;260
10.1.3;GENETIC CONTROL OF SPECIFIC IMMUNE SUPPRESSION;262
10.1.4;STRAIN DIFFERENCES IN THE SUPPRESSION BY GT
OF THE PRIMARY RESPONSE TO GT-MBSA;266
10.1.5;REFERENCES;268
10.1.6;DISCUSSION FOLLOWING BARUJ BENACERRAF;272
10.2;CHAPTER 17. FUNCTIONAL ANALYSIS OF la ANTIGENS
IN RELATION TO GENETIC CONTROL OF THE IMMUNE RESPONSE;280
10.2.1;INTRODUCTION;280
10.2.2;la ANTIGEN EXPRESSION ON B CELL
SUBPOPULATIONS;282
10.2.3;la ANTIGEN EXPRESSION ON T CELL SUBPOPULATIONS;286
10.2.4;DISCUSSION;293
10.2.5;ACKNOWLEDGMENTS;296
10.2.6;REFERENCES;297
10.2.7;DISCUSSION FOLLOWING HUGH McDEVITT;299
10.3;CHAPTER 18.
H-2 LINKED IMMUNE RESPONSE GENES: MULTIPLICITY AND FUNCTIONAL COMPLEMENTATION;306
10.3.1;ACKNOWLEDGEMENTS;309
10.3.2;REFERENCES;309
10.4;CHAPTER 19. H-3-LINKED UNRESPONSIVENESS TO EA-1 AND H-13
ANTIGENS;312
10.4.1;INTRODUCTION;312
10.4.2;EVIDENCE FOR THE MAP POSITION OF IR-2;313
10.4.3;UNRESPONSIVENESS OF YBR MICE MADE TOLERANT
OF BALB CELLS;314
10.4.4;H-3-LINKED LOW RESPONSE TO H-13 ANTIGENS;315
10.4.5;CONCLUSION;315
10.4.6;ACKNOWLEDGEMENTS;318
10.4.7;REFERENCES;318
10.5;CHAPTER 20. IMMUNE RESPONSES OF MICE AGAINST MODIFIED RANDOM POLYMERS
OF AMINO ACIDS, AND IMPLICATIONS IN GENE CONTROL;320
10.5.1;INTRODUCTION;320
10.5.2;RESPONSE TO GL COPOLYMERS MODIFIED WITH VARIOUS AMINO ACIDS;321
10.5.3;DISCUSSION;324
10.5.4;ACKNOWLEDGMENTS;327
10.5.5;REFERENCES;328
10.6;CHAPTER 21. A POSSIBLE FUNCTION FOR PRODUCTS OF THE MAJOR HISTOCOMPATIBILITY
COMPLEX IN HUMORAL IMMUNITY;330
10.6.1;INTRODUCTION;330
10.6.2;MATERIALS AND METHODS;331
10.6.3;RESULTS;331
10.6.4;DISCUSSION;333
10.6.5;REFERENCES;335
10.7;GENERAL DISCUSSION - SESSION III:
IMMUNE RESPONSE (Ir) GENE SYSTEMS;336
10.8;COMMENTARY;344
11;SESSION IV:
Genetic Control of Cell Interactions;356
11.1;CHAPTER 22. MACROPHAGE-T LYMPHOCYTE INTERACTION: THE CELLULAR BASIS
FOR GENETIC CONTROL OF ANTIGEN RECOGNITION;358
11.1.1;I. MACROPHAGE FUNCTION IN ANTIGEN SPECIFIC T CELL ACTIVATION;358
11.1.2;II. HOW DO
MACROPHAGES INTERACT WITH LYMPHOCYTES;360
11.1.3;III. IMMUNE RESPONSE GENE FUNCTION IN MACROPHAGE-T
LYMPHOCYTE INTERACTION;362
11.1.4;IV. GENETIC ANALYSIS OF DETERMINANTS MEDIATING MACROPHAGE
T-LYMPHOCYTE INTERACTION;365
11.1.5;V. ROLE OF MACROPHAGE-ASSOCIATED ANTIGEN IN THE
REGULATION OF GENETIC CONTROL OF THE IMMUNE RESPONSE;368
11.1.6;REFERENCES;372
11.1.7;DISCUSSION FOLLOWING ALAN ROSENTHAL;374
11.2;CHAPTER 23. GENETIC CONTROL OF LYMPHOCYTE INTERACTIONS AND
DIFFERENTIATION;378
11.2.1;EVIDENCE FOR GENETIC RESTRICTIONS IN COOPERATIVE T-B CELL
INTERACTIONS;379
11.2.2;EVIDENCE FOR FUNCTIONAL INTERRELATIONSHIPS BETWEEN CI AND Ir
GENES;387
11.2.3;THE CONCEPTS OF "ADAPTIVE DIFFERENTIATION"
AND "HAPLOTYPE PREFERENCE";396
11.2.4;CONCLUSION;404
11.2.5;ACKNOWLEDGMENTS;405
11.2.6;REFERENCES;406
11.2.7;DISCUSSION FOLLOWING DAVID KATZ;409
11.3;CHAPTER 24. STIMULATION OF ANTIBODY RESPONSES IN VITRO BY
ANTIGEN-BEARING SYNGENEIC AND ALLOGENEIC MACROPHAGES;414
11.3.1;INTRODUCTION;414
11.3.2;EXPERIMENTAL SYSTEM;416
11.3.3;ABILITY OF SYNGENEIC AND ALLOGENEIC MACROPHAGES TO
SUPPORT DEVELOPMENT OF PRIMARY ANTIBODY RESPONSES IN VITRO;416
11.3.4;ABILITY OF SYNGENEIC AND ALLOGENEIC MACROPHAGES TO SUPPORT DEVELOPMENT OF SECONDARY ANTIBODY
RESPONSES IN VITRO;418
11.3.5;DISCUSSION;421
11.3.6;ACKNOWLEDGEMENTS;423
11.3.7;REFERENCES;423
11.4;CHAPTER 25. H-2 LINKED Ir GENE REGULATION OF DELAYED-TYPE
HYPERSENSITIVITY IN MICE;426
11.4.1;INTRODUCTION;426
11.4.2;METHODS;426
11.4.3;RESULTS AND DISCUSSION;427
11.4.4;SUMMARY;436
11.4.5;REFERENCES;437
11.5;CHAPTER 26. DIFFERENTIAL EXPRESSION OF la ANTIGENS ON SUPPRESSOR T
CELLS, HELPER T CELLS AND B PRECURSOR CELLS;440
11.5.1;la ANTIGENS ON FUNCTIONAL LYMPHOCYTE
SUBPOPULATIONS;442
11.5.2;ARE la ANTIGENS SECRETED BY
ACTIVATED LYMPHOCYTES;445
11.5.3;ACKNOWLEDGEMENTS;446
11.5.4;REFERENCES;446
11.6;CHAPTER 27. EFFECTIVE ALLOGENEIC T CELL-B CELL INTERACTION
IN CHIMERIC MICE;448
11.6.1;INTRODUCTION;448
11.6.2;RESULTS;448
11.6.3;ACKNOWLEDGMENTS;454
11.6.4;REFERENCES;455
11.7;GENERAL DISCUSSION - SESSION IV:
GENETIC CONTROL OF CELL INTERACTIONS;456
12;SESSION V: Idiotypic Determinants on T Cell
Receptors;466
12.1;CHAPTER 28. T LYMPHOCYTE RECEPTOR ANALYSIS
BY ANTI - IDIOTYPIC STIMULATION;468
12.1.1;INTRODUCTION;468
12.1.2;SENSITIZATION BY ANTI-IDIOTYPIC ANTIBODY;470
12.1.3;HELPER CELLS INDUCED BY ANTI-IDIOTYPIC ANTI
BODYBEAR IDIOTYPIC RECEPTOR MOLECULES;472
12.1.4;ACKNOWLEDGEMENTS;477
12.1.5;REFERENCES;477
12.1.6;DISCUSSION FOLLOWING KLAUS RAJEWSKY;479
12.2;CHAPTER 29.
IDIOTYPIC RECEPTORS FOR ANTIGEN ON T LYMPHOCYTES;484
12.2.1;INTRODUCTION;485
12.2.2;DEMONSTRATION OF ANTI-IDIOTYPIC ANTIBODIES REACTIVE WITH
BOTH T AND B RECEPTORS FOR THE SAME ANTIGENIC DETERMINANTS;486
12.2.3;VISUALIZATION: FREQUENCY-DETERMINATION AND PHYSICAL
ISOLATION OF IDIOTYPE POSITIVE T LYMPHOCYTES;488
12.2.4;A SPECULATIVE DISCUSSION OF THE FREQUENCY OF
IDIOTYPE-POSITIVE LYMPHOCYTES;490
12.2.5;PRESENCE OF IDIOTYPIC MOLECULES WITH ANTI-AG-B ACTIVITY
IN SERUM AND URINE OF NORMAL ADULT RATS;491
12.2.6;DEMONSTRATION OF CELLULAE ORIGIN OF NATURALLY PRODUCED,
IDIOTYPE-POSITIVE MOLECULES WITH REACTIVITY AGAINST Ag-B ANTIGENS;493
12.2.7;SPECULATIONS AS TO THE STRUCTURE OF
THE T CELL RECEPTOR FOR ANTIGEN;495
12.2.8;REFERENCES;497
12.2.9;ACKNOWLEDGEMENTS;498
12.2.10;DISCUSSION FOLLOWING HANS WIGZELL;499
13;SESSION VI: Properties of Histocompatibility Gene Products Involved in Regulation of Immune Responses;506
13.1;CHAPTER 30. THE NATURE OF ANTIGEN SPECIFIC T CELL FACTORS INVOLVED IN
THE GENETIC REGULATION OF IMMUNE RESPONSES;508
13.1.1;INTRODUCTION;509
13.1.2;SPECIFICITY OF T CELL FACTORS;510
13.1.3;ISOLATION AND PURIFICATION OF A T CELL FACTOR PRODUCED WITH
(T,G)-A--L;513
13.1.4;THE T CELL FACTOR SPECIFIC FOR (T,G)-Pro—L IS A PRODUCT OF
THE H-2 COMPLEX;518
13.1.5;EFFECT OF T CELL FACTORS ON THE SPLENIC LEVELS OF CYCLIC AMP IN MICE;524
13.1.6;CONCLUDING REMARKS;525
13.1.7;ACKNOWLEDGMENTS;526
13.1.8;REFERENCES;527
13.1.9;DISCUSSION FOLLOWING EDNA MOZES;529
13.2;CHAPTER 31. CHARACTERIZATION OF THE ANTIGEN-SPECIFIC SUPPRESSIVE T CELL FACTOR WITH SPECIAL REFERENCE TO
THE EXPRESSION OF J REGION GENES;536
13.2.1;INTRODUCTION;537
13.2.2;GENERAL FEATURES OF THE ANTIGEN-SPECIFIC
SUPPRESSIVE T CELL FACTOR;538
13.2.3;THE ANTIGEN-SPECIFIC SUPPRESSIVE T CELL FACTOR AS AN I
REGION GENE PRODUCT;541
13.2.4;REQUIREMENT FOR HISTOCOMPATIBILITY IN THE EFFECTIVE
SUPPRESSION BY THE T CELL FACTOR IN DIFFERENT MOUSE STRAINS;547
13.2.5;DISCUSSION;552
13.2.6;ACKNOWLEDGEMENTS;555
13.2.7;REFERENCES;556
13.2.8;DISCUSSION FOLLOWING TOMIO TADA;558
13.3;CHAPTER 32.
HISTOCOMPATIBILITY GENE PRODUCTS AS MEDIATORS OF LYMPHOCYTE INTERACTIONS;564
13.3.1;INTRODUCTION;564
13.3.2;GENETIC AND CELLULAR REQUIREMENTS FOR AEF PRODUCTION;565
13.3.3;BIOLOGICAL PROPERTIES OF AEF;566
13.3.4;PHYSICOCHEMICAL AND BIOCHEMICAL PROPERTIES OF AEF;566
13.3.5;IMMUNOLOGICAL AND IMMUNOCHEMICAL PROPERTIES OF AEF;567
13.3.6;RELATIONSHIP OF AEF TO OTHER BIOLOGICALLY ACTIVE FACTORS
POSSESSING HISTOCOMPATIBILITY ANTIGEN DETERMINANTS;572
13.3.7;CONCLUSIONS;573
13.3.8;ACKNOWLEDGMENTS;573
13.3.9;REFERENCES;574
13.4;CHAPTER 33.
I-REGION GENE PRODUCTS IN CELL COOPERATION;576
13.4.1;REFERENCES;588
13.5;CHAPTER 34. SUPPRESSIVE ACTIVITY OF LYMPHOID CELL EXTRACTS FROM NON-RESPONDER MICE INJECTED WITH THE TERPOLYMER L-GLUTAMIC ACID60- L-ALANINE30- L-TYROSINE10
(GAT);592
13.5.1;INTRODUCTION;592
13.5.2;COMPARISON OF LYMPHOID CELL EXTRACTS FROM
CONTROL AND GAT-PRIMED MICE;593
13.5.3;ANTIGENIC SPECIFICITY OF THE EXTRACT;596
13.5.4;ESTIMATE OF MOLECULAR WEIGHT;596
13.5.5;ACKNOWLEDGEMENTS;597
13.5.6;REFERENCES;598
13.6;CHAPTER 35. ANTI -ß2MICROGLOBULIN - A SELECTIVE PBA FOR HUMAN AND MOUSE B
LYMPHOCYTES;602
13.6.1;INTRODUCTION;602
13.6.2;THE ACTIVE MITOGENIC PRINCIPLE IN ANTISERA AGAINST
ß2MICROGLOBULIN;603
13.6.3;OPTIMAL CONDITIONS FOR MITOGENICITY OF ANTIBODIES TO
ß2MICROGLOBULIN;604
13.6.4;B CELLS ARE DIRECTLY ACTIVATED BY ANTI-
ß2MICROGLOBULIN;606
13.6.5;DOES ANTI-ß2MICROGLOBULIN ACTIVATE A SPECIFIC SUBSET
OF LYMPHOCYTES?;607
13.6.6;WHICH CELL RECEPTOR IS RESPONSIBLE FOR THE MITOGENIC
ACTION OF ANTI ß2MICROGLOBULIN?;611
13.6.7;ACKNOWLEDGEMENTS;613
13.6.8;REFERENCES;614
13.7;GENERAL DISCUSSION - SESSION VI: PROPERTIES OF HISTOCOMPATIBILITY GENE PRODUCTS INVOLVED IN
REGULATION OF IMMUNE RESPONSES;616
14;SESSION VII: Biochemistry and Immunocytology of Cell Surface Products of the Major Histocompatibility Complex;624
14.1;CHAPTER 36.
CYTOLOGICAL ANALYSIS OF HISTOCOMPATIBILITY MOLECULES;626
14.1.1;INTRODUCTION;626
14.1.2;MAPPING STUDIES;627
14.1.3;REDISTRIBUTION;631
14.1.4;CO-CAPPING;633
14.1.5;ACKNOWLEDGEMENTS;637
14.1.6;REFERENCES;637
14.1.7;DISCUSSION FOLLOWING EMIL UNANUE;640
14.2;CHAPTER 37. ISOLATION AND STRUCTURE OF PRODUCTS OF THE HUMAN
HISTOCOMPATIBILITY GENE COMPLEX;644
14.2.1;INTRODUCTION;644
14.2.2;HL-A ANTIGENS FROM HUMAN LYMPHOCYTES;644
14.2.3;B CELL SPECIFIC ANTIGENS FROM HUMAN LYMPHOCYTES;656
14.2.4;ACKNOWLEDGMENTS;660
14.2.5;REFERENCES;665
14.2.6;DISCUSSION FOLLOWING JACK STROMINGER;667
14.3;CHAPTER 38. STUDIES ON THE CHEMICAL BASIS OF VARIABILITY AND THE COMPLEX CELLULAR EXPRESSION OF THE H-2K and H-2D PRODUCTS;670
14.3.1;INTRODUCTION;671
14.3.2;STUDIES ON THE PEPTIDE ANALYSIS OF SELECTED H-2K AND H-2D GENE PRODUCTS;672
14.3.3;STUDIES ON THE POLYMORPHISM AND INTRAMOLECULAR ARRANGEMENT OF THE H-2 GLYCOPROTEINS;677
14.3.4;STUDIES ON SOMATIC CELL VARIANTS IN H-2
EXPRESSION;681
14.3.5;CONCLUDING THOUGHTS;684
14.3.6;ACKNOWLEDGMENTS;685
14.3.7;REFERENCES;686
14.3.8;DISCUSSION FOLLOWING STANLEY NATHENSON;688
14.4;CHAPTER 39.
STRUCTURE AND BIOLOGICAL ACTIVITY OF H-2 ANTIGENS;690
14.4.1;INTRODUCTION;690
14.4.2;STRUCTURE OF H-2 ANTIGENS;691
14.4.3;COMPARISON OF PARTIAL AMINO ACID SEQUENCES;694
14.4.4;FUNCTIONAL STUDIES;696
14.4.5;REFERENCES;698
14.5;CHAPTER 40. GENETIC AND
EVOLUTIONARY IMPLICATIONS OF THE PARTIAL AMINO ACID SEQUENCES OF H-2K AND H-2D ALLOANTIGENS;700
14.5.1;INTRODUCTION;700
14.5.2;MATERIALS AND METHODS;702
14.5.3;RESULTS;702
14.5.4;DISCUSSION;705
14.5.5;ACKNOWLEDGMENTS;709
14.5.6;REFERENCES;710
14.6;CHAPTER 41.
THE CHEMISTRY OF MOUSE AND GUINEA PIG la ANTIGENS;714
14.6.1;INTRODUCTION;714
14.6.2;METHODS;715
14.6.3;CHEMISTRY AND STRUCTURE;716
14.6.4;IMMUNOGENETIC STUDIES;718
14.6.5;TISSUE DISTRIBUTION;721
14.6.6;QUESTIONS TO BE ANSWERED;723
14.6.7;REFERENCES;723
14.7;GENERAL DISCUSSION - SESSION VII: BIOCHEMISTRY AND IMMUNOCYTOLOGY OF CELL SURFACE PRODUCTS
OF THE MAJOR HISTOCOMPATIBILITY COMPLEX;726
15;SESSION VIII: Interrelationships Between Products of the Major Histocompatibility Complex and Their Relevance to Disease;736
15.1;CHAPTER 42. GENERAL DISCUSSION - SESSION VIII: INTERRELATIONSHIPS BETWEEN PRODUCTS OF THE MAJOR
HISTOCOMPATIBILITY COMPLEX AND THEIR RELEVANCE TO DISEASE;738
15.1.1;1. a) SPECIFICITY OF H-LINKED
Ir GENE FUNCTION;745
15.1.2;1. b) MICROHETEROGENEITY OF la MOLECULES;751
15.1.3;2. EVIDENCE FOR EXISTENCE OF A DISTINCT I-B SUB-REGION;754
15.1.4;3. a,b,c) NATURE OF THE ANTIGEN RECEPTOR ON T CELL FACTORS AND RELATIONSHIP TO VH REGIONS AND Ig IDIOTYPES; THEIR SPECIFICITY RANGE AS COMPARED TO IMMUNOGLOBULINS; AND POSSIBLE EXISTENCE OF DUAL RECOGNITION SYSTEMS AT THE T CELL LEVEL AND AT OTHER LEVELS;756
15.1.5;4. SIMILARITIES AND DIFFERENCES BETWEEN HELPER AND SUPPRESSOR FACTORS;771
15.1.6;5. BASIS FOR THE LARGE NUMBERS OF ALLOSPECIFIC T CELLS RECOGNIZING MHC ANTIGENS;775
15.1.7;6. THE PHENOMENON OF CIS-TRANS PREFERENCE IN COMPLEMENTATION OF IT GENES AND ITS RELEVANCE TO
LINKAGE DISEQUILIBRIUM IN THE MHC;786
15.1.8;7. THE BASIS FOR PRESENCE OR ABSENCE OF GENETIC RESTRICTIONS IN
T-B CELL COOPERATION — ADAPTATION OR SELECTION;788
15.1.9;RELATIONSHIP OF THE MHC TO HUMAN DISEASE;797

Leseproben

Participants
D. Bernard Amos,     Department of Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina 27710 Dieter Armerding,     Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Fritz H. Bach,     Immunobiology Research Center, University of Wisconsin, Madison, Wisconsin 53706 Baruj Benacerraf,     Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Kathleen Bechtol,     Department of Zoology, University of Oxford, South Parks Road, Oxford OX 1 3PS England Bruce A. Cunningham,     Rockefeller University, New York, New York 10021 Jean Dausset,     Université de Paris VII, Hospital St. Louis, Place du Docteur-Fournier, Paris, France Martin E. Dorf,     Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Bo Dupont,     Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021 David L. Gasser,     Department of Human Genetics, University of Pennsylvania, Philadelphia, Pennsylvania 19174 Richard Gershon,     Department of Pathology, Yale Medical School, New Haven, Connecticut 06510 Ira Green,     Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014 Howard Grey,     National Jewish Hospital and Research Center, Denver, Colorado 80206 Günter Hämmerling,     Institut für Genetik, der Universität zu Köln, 5 Köln-Lindenthal, Weyertal 121 Germany Leroy Hood,     Department of Biology, California Institute of Technology, Pasadena, California 91109 Bernard W. Janicki,     Extramural Programs, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014 Judith Kapp,     Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 David H. Katz,     Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Rolf Kiessling,     Department of Tumor Biology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden George Klein,     Department of Tumor Biology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden Jan Klein,     Department of Microbiology, University of Texas, Southwestern Medical School, Dallas, Texas 75235 Henry G. Kunkel,     Rockefeller University, New York, New York 10021 Rose Lieberman,     Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014 Paul H. Maurer,     Department of Biochemistry, Jefferson Medical College, Philadelphia, Pennsylvania 19107 Hugh O. McDevitt,     Department of Medicine, Stanford University Medical Center, Stanford, California 94305 Tommaso Meo,     Department of Genetics, Washington University School of Medicine, St. Louis, Missouri 63110 J.F.A.P. Miller,     The Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria 3050, Australia Erna Möller,     Division of Immunobiology, Karolinska Institute, Wallenberg Laboratory, 104 05 Stockholm 50, Sweden Edna Mozes,     Department of Chemical Immunology, Weizmann Institute of Science, Rehovoth, Israel Alan J. Munro,     Immunology Division, Department of Pathology, Tennis Court Road, Cambridge, England Stanley G. Nathenson,     Dept. Microbiology and Immunobiology, Albert Einstein College of Medicine, Bronx, New York 10461 G.J.V. Nossal,     The Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria 3050, Australia William E. Paul,     Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014 Carl W. Pierce,     Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Klaus Rajewsky,     Institut für Genetik der, Universität zu Köln, 5 Köln-Lindenthal, Weyertal 121, Germany Alan Rosenthal,     Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014 David H. Sachs,     Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014 Michael Sela,     Department of Chemical Immunology, Weizmann Institute of Science, Rehovoth, Israel Gene M. Shearer,     Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014 Ethan M. Shevach,     Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014 Donald C. Shreffler,     Department of Genetics, Washington University School of Medicine, St. Louis, Missouri 63110 Morten Simonsen,     University of Copenhagen, Nørre Alle 71, DK 2100 Copenhagen Ø, Denmark Jack H. Stimpfling,     McLaughlin Research Institute, Columbus Hospital, Great Falls, Montana 59401 Jack L. Strominger,     Department of Biochemistry and Molecular Biology, Harvard University, Cambridge, Massachusetts 02138 Tomio Tada,     Immunology Research Laboratories, School of Medicine, Chiba University, Chiba, Japan Michael Taussig,     Basel Institute for Immunology, 478, Grenzacherstrasse CH 4058, Basel, Switzerland Jonathan W. Uhr,     Department of Microbiology, University of Texas, Southwestern Medical School, Dallas, Texas 75235 Emil R. Unanue,     Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Harald von Boehmer,     Basel Institute for Immunology, 487 Grenzacherstrasse CH 4058, Basel, Switzerland Jon J. van Rood,     Department of Immunohematology, University Hospital, Leiden, The Netherlands Ellen Vitetta,     Department of Microbiology, University of Texas, Southwestern Medical School, Dallas, Texas 75235 Hans Wigzell,     Department of Immunology, Uppsala University, Uppsala, Sweden Darcy B. Wilson,     Department of Pathology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19174 Edmond J. Yunis,     University of Minnesota Hospital,...